Targets for Medical Therapy to Limit Abdominal Aortic Aneurysm Progression
Theophilus I. Emeto, Sai-Wang Seto and Jonathan Golledge
Affiliation: Vascular Biology Unit, Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University Townsville, QLD 4811, Australia.
Keywords: Abdominal aortic aneurysm, animal models, clinical trial, pharmacotherapy.
Abdominal aortic aneurysm (AAA) is an important cause of mortality in older adults. Most AAAs are asymptomatic
and screening programs have been introduced to identify AAAs at an early stage in some countries. There is currently
no accepted therapy for early stage or small AAAs, which are frequently identified by such programs. In this review,
we discuss work underway to identify targets for medical treatments to limit progression of small AAAs. Specifically
we discuss studies, which have examined the potential of targeting inflammation, proteolysis, the renin-angiotensin
system, the coagulation system and sex hormones as approaches to limiting AAA pathogenesis. As yet, none of the treatment
targets have translated into an agent, which can effectively reduce AAA progression in clinical practice.
Rights & PermissionsPrintExport